Downregulation of insulin-like growth factor-binding protein 7 in cisplatin-resistant non-small cell lung cancer

References

• Sánchez-Pérez I, Martínez-Gomariz M, Williams D, Keyse SM, Perona R. CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin. Oncogene 2000; 19:5142 - 5152; PMID: 11064451; http://dx.doi.org/10.1038/sj.onc.1203887
   PubMed Web of Science ®Google Scholar
• Burger AM, Leyland-Jones B, Banerjee K, Spyropoulos DD, Seth AK. Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer. Eur J Cancer 2005; 41:1515 - 1527; PMID: 15979304; http://dx.doi.org/10.1016/j.ejca.2005.04.023
   PubMed Web of Science ®Google Scholar
• Suzuki H, Igarashi S, Nojima M, Maruyama R, Yamamoto E, Kai M, et al. IGFBP7 is a p53 responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. Carcinogenesis 2010; 31:342 - 349; PMID: 19638426; http://dx.doi.org/10.1093/carcin/bgp179
   PubMed Web of Science ®Google Scholar
• Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008; 132:363 - 374; PMID: 18267069; http://dx.doi.org/10.1016/j.cell.2007.12.032
   PubMed Web of Science ®Google Scholar
• Wajapeyee N, Kapoor V, Mahalingam M, Green MR. Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines. Mol Cancer Ther 2009; 8:3009 - 3014; PMID: 19861408; http://dx.doi.org/10.1158/1535-7163.MCT-09-0470
   PubMed Web of Science ®Google Scholar
• Hinoue T, Weisenberger DJ, Pan F, Campan M, Kim M, Young J, et al. Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS ONE 2009; 4:e8357; PMID: 20027224; http://dx.doi.org/10.1371/journal.pone.0008357
   PubMed Web of Science ®Google Scholar
• Tomimaru Y, Eguchi H, Wada H, Kobayashi S, Marubashi S, Tanemura M, et al. IGFBP7 down-regulation is associated with tumor progression and clinical outcome in hepatocellular carcinoma. Int J Cancer 2011; In press PMID: 21328580; http://dx.doi.org/10.1002/ijc.25994
   PubMed Web of Science ®Google Scholar
• Nousbeck J, Sarig O, Avidan N, Indelman M, Bergman R, Ramon M, et al. Insulin-like growth factor-binding protein 7 regulates keratinocyte proliferation, differentiation and apoptosis. J Invest Dermatol 2010; 130:378 - 387; PMID: 19710688; http://dx.doi.org/10.1038/jid.2009.265
   PubMed Web of Science ®Google Scholar
• Smith P, Nicholson LJ, Syed N, Payne A, Hiller L, Garrone O, et al. Epigenetic inactivation implies independent functions for insulin-like growth factor binding protein (IGFBP)-related protein 1 and the related IGFBPL1 in inhibiting breast cancer phenotypes. Clin Cancer Res 2007; 13:4061 - 4068; PMID: 17634530; http://dx.doi.org/10.1158/1078-0432.CCR-06-3052
   PubMed Web of Science ®Google Scholar
• Tomimaru Y, Eguchi H, Wada H, Noda T, Murakami M, Kobayashi S, et al. Insulin-like growth factor-binding protein 7 alters the sensitivity to interferon-based anticancer therapy in hepatocellular carcinoma cells. Br J Cancer 2010; 102:1483 - 1490; PMID: 20407444; http://dx.doi.org/10.1038/sj.bjc.6605669
   PubMed Web of Science ®Google Scholar
• Camps M, Nichols A, Arkinstall S. Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J 2000; 14:6 - 16; PMID: 10627275
   PubMed Web of Science ®Google Scholar
• Farooq A, Zhou MM. Structure and regulation of MAPK phosphatases. Cell Signal 2004; 16:769 - 779; PMID: 15115656; http://dx.doi.org/10.1016/j.cellsig.2003.12.008
   PubMed Web of Science ®Google Scholar
• Chattopadhyay S, Machado-Pinilla R, Manguan-García C, Belda-Iniesta C, Moratilla C, Cejas P, et al. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer. Oncogene 2006; 25:3335 - 3345; PMID: 16462770; http://dx.doi.org/10.1038/sj.onc.1209364
   PubMed Web of Science ®Google Scholar
• Cortes-Sempere M, Chattopadhyay S, Rovira A, Rodriguez-Fanjul V, Belda-Iniesta C, Tapia M, et al. MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer. Cancer Lett 2009; 286:206 - 216; PMID: 19553005; http://dx.doi.org/10.1016/j.canlet.2009.05.029
   PubMed Web of Science ®Google Scholar
• Cui Y, Parra I, Zhang M, Hilsenbeck SG, Tsimelzon A, Furukawa T, et al. Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res 2006; 66:5950 - 5959; PMID: 16740736; http://dx.doi.org/10.1158/0008-5472.CAN-05-3243
   PubMed Web of Science ®Google Scholar
• Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, et al. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 1994; 369:156 - 160; PMID: 8177321; http://dx.doi.org/10.1038/369156a0
   PubMed Web of Science ®Google Scholar
• Gu F, Ma Y, Zhang Z, Zhao J, Kobayashi H, Zhang L, et al. Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma. Oncol Rep 2010; 23:671 - 676; PMID: 20127005
   PubMed Web of Science ®Google Scholar
• Selvendiran K, Bratasz A, Kuppusamy ML, Tazi MF, Rivera BK, Kuppusamy P. Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3. Int J Cancer 2009; 125:2198 - 2204; PMID: 19623660; http://dx.doi.org/10.1002/ijc.24601
   PubMed Web of Science ®Google Scholar
• Ikuta K, Takemura K, Kihara M, Nishimura M, Ueda N, Naito S, et al. Overexpression of constitutive signal transducer and activator of transcription 3 mRNA in cisplatin-resistant human non-small cell lung cancer cells. Oncol Rep 2005; 13:217 - 222; PMID: 15643501
   PubMed Web of Science ®Google Scholar
• Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264:1415 - 1421; PMID: 8197455; http://dx.doi.org/10.1126/science.8197455
   PubMed Web of Science ®Google Scholar
• Ihle JN. Cytokine receptor signalling. Nature 1995; 377:591 - 594; PMID: 7566171; http://dx.doi.org/10.1038/377591a0
   PubMed Web of Science ®Google Scholar
• Leppä S, Saffrich R, Ansorge W, Bohmann D. Differential regulation of c-Jun by ERK and JNK during PC12 cell differentiation. EMBO J 1998; 17:4404 - 4413; PMID: 9687508; http://dx.doi.org/10.1093/emboj/17.15.4404
   PubMed Web of Science ®Google Scholar
• Shi M, Liu D, Duan H, Han C, Wei B, Qian L, et al. Catecholamine up-regulates MMP-7 expression by activating AP-1 and STAT3 in gastric cancer. Mol Cancer 2010; 9:269; PMID: 20939893
   PubMed Web of Science ®Google Scholar
• Gorelik B, Ziv I, Shohat R, Wick M, Hankins WD, Sidransky D, et al. Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model. Cancer Res 2008; 68:9033 - 9040; PMID: 18974149; http://dx.doi.org/10.1158/0008-5472.CAN-08-1723
   PubMed Web of Science ®Google Scholar
• Chen Y, Cui T, Knösel T, Yang L, Zöller K, Petersen I. IGFBP7 is a p53 target gene inactivated in human lung cancer by DNA hypermethylation. Lung Cancer 2011; 73:38 - 44; PMID: 21095038; http://dx.doi.org/10.1016/j.lungcan.2010.10.015
   PubMed Web of Science ®Google Scholar
• Chang X, Monitto CL, Demokan S, Kim MS, Chang SS, Zhong X, et al. Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res 2010; 70:2870 - 2879; PMID: 20215521; http://dx.doi.org/10.1158/0008-5472.CAN-09-3427
   PubMed Web of Science ®Google Scholar
• Messina S, Frati L, Leonetti C, Zuchegna C, Di Zazzo E, Calogero A, et al. Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas. Oncogene 2011; 30:3813 - 3820; PMID: 21499306; http://dx.doi.org/10.1038/onc.2011.99
   PubMed Web of Science ®Google Scholar
• Bermudez O, Jouandin P, Rottier J, Bourcier C, Pagès G, Gimond C. Post-transcriptional regulation of the DUSP6/MKP-3 phosphatase by MEK/ERK signaling and hypoxia. J Cell Physiol 2011; 226:276 - 284; PMID: 20665674; http://dx.doi.org/10.1002/jcp.22339
   PubMed Web of Science ®Google Scholar
• Park JC, Chae YK, Son CH, Kim MS, Lee J, Ostrow K, et al. Epigenetic silencing of human T (brachyury homologue) gene in non-small-cell lung cancer. Biochem Biophys Res Commun 2008; 365:221 - 226; PMID: 17980147; http://dx.doi.org/10.1016/j.bbrc.2007.10.144
   PubMed Web of Science ®Google Scholar
• Caney C, Bulmer JT, Singh G, Lukka H, Rainbow AJ. Pre-exposure of human squamous carcinoma cells to low-doses of gamma-rays leads to an increased resistance to subsequent low-dose cisplatin treatment. Int J Radiat Biol 1999; 75:963 - 972; PMID: 10465362; http://dx.doi.org/10.1080/095530099139728
   PubMed Web of Science ®Google Scholar
• Shen DW, Akiyama S, Schoenlein P, Pastan I, Gottesman MM. Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes. Br J Cancer 1995; 71:676 - 683; PMID: 7710928; http://dx.doi.org/10.1038/bjc.1995.134
   PubMed Web of Science ®Google Scholar
• Kim MS, Chang X, LeBron C, Nagpal JK, Lee J, Huang Y, et al. Neurofilament heavy polypeptide regulates the Akt-beta-catenin pathway in human esophageal squamous cell carcinoma. PLoS ONE 2010; 5:e9003; PMID: 20140245; http://dx.doi.org/10.1371/journal.pone.0009003
   PubMedGoogle Scholar